Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27664795 | 0.84 | TSHR (0.52) | TSHRGPR35TDP1ALDH1A1MAPT | |
| SCHEMBL7615798 | 0.77 | TDP1 (0.40) | TSHRGPR35TDP1ALDH1A1MEN1 | |
| SCHEMBL221622 | 0.77 | TDP1 (0.56) | TSHRGPR35TDP1ALDH1A1MAPT | |
| SCHEMBL3036771 | 0.77 | GPR35 (0.56) | GPR35TDP1ALDH1A1MEN1MAPT | |
| SCHEMBL7232153 | 0.77 | VCAM1 (0.52) | TSHRGPR35TDP1ALDH1A1MEN1 | |
| Water SCHEMBL27294140 | 0.74 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1MEN1 | |
| SCHEMBL27715528 | 0.73 | LOXL2 (0.39) | TSHRGPR35TDP1ALDH1A1MEN1 | |
| SCHEMBL4894100 | 0.73 | VCAM1 (0.44) | TDP1ALDH1A1MEN1POLBMAPT | |
| SCHEMBL196663 | 0.72 | ALDH1A1 (0.56) | TSHRTDP1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL11796324 | 0.72 | ERN1 (0.50) | TSHRGPR35ALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2644599-A1 | Method for preparing 1-substituted-4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-05-24 | — | — | US | disclosed |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| EP-2429292-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | Georgia State University Research Foundation, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8129544-B2 | Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| WO-2010129858-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | WO | disclosed |
| US-7807843-B2 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
| US-4385176-A | RING EXPANSION USING A LEWIS ACID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-24 | — | — | US | disclosed |
| US-4308380-A | 2-Lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-29 | — | — | US | disclosed |
| US-4214094-A | ANTILIPEMIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| US-4203897-A | Penam derivatives | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1980-05-20 | — | — | US | disclosed |
| US-4113940-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4091210-A | Preparation of 3-alkyl-3-cephem-4-carboxylic acid compounds from dithio isopropenyl azetidine carboxylic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-05-23 | — | — | US | disclosed |
| US-4084049-A | CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-04-11 | — | — | US | disclosed |
| US-3984397-A | CYCLIZATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3954732-A | BACTERICIDAL PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | CBR1, CBR3, DCXR | TSHR 370/4885GPR35 4530/4885TDP1 3348/4885 |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | TSHR 3262/4885GPR35 4420/4885TDP1 4024/4885 |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | TSHR 4473/4885GPR35 3866/4885TDP1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.